GlassScriptPhysician profile
Anis Ahmed
NPI 1407877202
$7,773.25
in general payments reported to CMS, 2019-2025
20 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $912 · 2021: $1,715 · 2022: $1,424 · 2023: $782 · 2024: $955 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.78 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,564.69 | 2019-2025 | Invega, Invega Sustenna, Spravato |
| Alkermes, INC. | $1,363.40 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $889.08 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $806.38 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $600.69 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $428.53 | 2020-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $370.16 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $336.22 | 2019-2022 | |
| Abbvie INC. | $324.40 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $287.10 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $264.07 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $203.88 | 2022-2025 | Fanapt, Hetlioz |
| Indivior INC. | $71.62 | 2022-2024 | Perseris |
| Jazz Pharmaceuticals INC. | $56.70 | 2021 | |
| Shire North American Group INC | $49.67 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $38.81 | 2020 | |
| Bausch Health US, LLC | $38.71 | 2019-2021 | |
| Allergan, INC. | $31.42 | 2019 | |
| Avanir Pharmaceuticals, INC. | $26.14 | 2019 | |
| Axsome Therapeutics, INC. | $21.58 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anis Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.